The Institute for Clinical and Economic Review (ICER) announced plans to review Novartis’ inclisiran and Esperion Therapeutics’ Nexletol for the treatment of high cholesterol.
According to a press release, the Food and Drug Administration (FDA) signed off on Nexletol in February. The agency is expected to make a decision on inclisiran by the end of this year.
An evidence report on high cholesterol will be presented to one of ICER’s independent councils in February next year.
To read the full press release on ICER’s site, click here.
